ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

High-dose gatifloxacin-based shorter treatment regimens for MDR/RR-TB

Nie, Qi; Tao, Lixuan; Li, Yingying; Chen, Nanshan; Chen, Hua; Zhou, Yong; Wang, Yanqiu; Chen, Huidong; Tang, Qiuping; Wang, Xianguang*; Huang, Chaolin*; Yang, Chengfeng*华中科技大学
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES2022-2DOI: 10.1016/j.ijid.2021.11.037
4被引7阅读
引用收藏
分享

摘要

Setting: The shorter treatment regimen (STR) for multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) has achieved successful outcomes in many countries. However, there are few studies on high-dose gatifloxacin-based STR with adverse drug reactions (ADRs) and management. @@@ Design: A prospective observational study was conducted with MDR/RR-TB patients who were treated with a standardized 9 or 12 - month regimen: including gatifloxacin (Gfx), clofazimine (Cfz), ethambutol (EMB), and pyrazinamide (PZA), and supplemented by amikacin (Am), isoniazid (INH), and prothionamide (Pto) during an intensive phase of 4 or 6 - month. Monitored ADRs monthly until treatment completion and then followed up every three months for one year. @@@ Results: Among the 42 eligible patients, 35 (83.3%) completed treatment successfully, 1 (2.4%) lost to follow-up (LTFU), and 6 (14.3%) failed due to ADRs, with no death. The most important ADR was drug-induced liver damage, which occurred in 24 out of 42 (57.1%) patients and resulted in 4 (9.5%) failed treatments and 4 (9.5%) adjusted treatments. QT interval prolongation occurred in 17 out of 42 (40.5%) patients, 9 (21.4%) of them with the corrected QT interval according to Fridericia (QTcF) > 500 ms resulting in 7 (16.7%) adjusted treatments. @@@ Conclusions: This study confirmed the effectiveness of the high-dose gatifloxacin-based STR but severe ADRs, especially hepatotoxicity and QT interval prolongation should never be ignored.

学科与关键词

关键词
Multidrug-Resistant tuberculosisMDR-TBShorter treatment regimenSTRGatifloxacinADR
相关
加载中…
  • Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
    Srivastava, Shashikant; Deshpande, Devyani; Magombedze, Gesham; Gumbo, Tawanda*Clinical Infectious Diseases, 2018, 67: S359-S364.被引 16
  • Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study
    van den Elsen, Simone H. J.; Sturkenboom, Marieke G. G.; Akkerman, Onno; Barkane, Linda; Bruchfeld, Judith; Eather, Geoffrey; Heysell, Scott K.; Hurevich, Henadz; Kuksa, Liga; Kunst, Heinke; Kuhlin, Johanna; Manika, Katerina; Moschos, Charalampos; Mpagama, Stellah G.; Munoz Torrico, Marcela; Skrahina, Alena; Sotgiu, Giovanni; Tadolini, Marina; Tiberi, Simon; Volpato, Francesca; van der Werf, Tjip S.; Wilson, Malcolm R.; Zuniga, Joaquin; Touw, Daan J.; Migliori, Giovanni B.BMJ Open, 2020, 10(6): e035350.被引 5
  • A Review of Clinical Pharmacokinetic and Pharmacodynamic Relationships and Clinical Implications for Drugs Used to Treat Multi-drug Resistant Tuberculosis
    Wilby, Kyle John*; Hussain, Farhat NazEUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2020, 45(3): 305-313.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
发表日期
2022-02
卷期
第 115 卷
页码
142-148
DOI
10.1016/j.ijid.2021.11.037
语言
ENGLISH
期刊等级
3区
成果收录
SCIE
资助标注
Medical research projects of the Health and Family Planning Commission of Wuhan Municipality [WX17Q28, WZ17B09]

作者

  • N

    Nie, Qi (第一作者)

    wuhan univ sci & technol

  • T

    Tao, Lixuan

    wuhan univ sci & technol

查看全部 12 位作者收起作者
  • L

    Li, Yingying

    huazhong univ sci & technol

  • C

    Chen, Nanshan

  • C

    Chen, Hua

  • Z

    Zhou, Yong

  • W

    Wang, Yanqiu

  • C

    Chen, Huidong

  • T

    Tang, Qiuping

  • W

    Wang, Xianguang (通讯)

  • H

    Huang, Chaolin (通讯)

  • Y

    Yang, Chengfeng (通讯)

    hubei prov ctr dis control & prevent

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417